Johnson & Johnson announced a $2 billion investment to expand its drug manufacturing capabilities in Holly Springs, North Carolina. The new facility, located at the Fujifilm Diosynth site, will cover more than 160,000 square feet and is expected to create approximately 120 jobs. This investment is part of Johnson & Johnson's broader $57 billion commitment to U.S. pharmaceutical manufacturing and aims to strengthen domestic supply chains amid looming drug import tariffs proposed by the Trump administration. President Donald Trump has threatened tariffs as high as 250% on pharmaceutical imports, prompting companies like Johnson & Johnson to increase onshore production. CEO Joaquin Duato highlighted the company's commitment to U.S. healthcare innovation, referencing the recent One Big Beautiful Bill Act. The new North Carolina plant is scheduled to open in the fall, with Johnson & Johnson and Regeneron as initial customers. This move aligns with a wider industry trend, with other major pharmaceutical companies such as Roche, AstraZeneca, Eli Lilly, and Gilead also committing billions to expand U.S. manufacturing capacity.